Saturday 17 January 2026

The Pharma Letter Podcast — Episode 36 — How blood cancer treatment is evolving in the Middle East

Biotechnology
8 December 2025

More on this story...

Biotechnology
Illuminating sickle cell disease - update 2025
4 November 2025
Pharmaceutical
Intratumoral cancer therapy market set to grow sharply through 2033
27 November 2025
Pharmaceutical
Emerging therapies expected to reshape endometrial cancer market landscape
7 November 2025


Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

EC approves Aspaveli for C3G and primary IC-MPGN
Biotechnology
EC approves Aspaveli for C3G and primary IC-MPGN
16 January 2026
Biotechnology
Chinese CDMO seeks to consolidate leadership in ADC space
16 January 2026
Pharmaceutical
Russian customers forced to save on drug purchases as crisis deepens
16 January 2026
Biotechnology
EC authorization for Waskyra for Wiskott-Aldrich syndrome
16 January 2026
Pharmaceutical
Reported delays to FDA reviews under new fast-track program
16 January 2026
Generics
STADA’s Frank Staud takes on additional role as head of global government affairs
16 January 2026
Pharmaceutical
Avid Bioservices taps new CBO as it leans into growth
16 January 2026

Company Spotlight

Alloy Therapeutics
A privately held biotechnology platform company based in the Boston, Massachusetts area. It operates as a partner-facing “ecosystem” business supporting biologics discovery and development across multiple modalities, and it also participates in company creation through its venture studio model.


More Features in Biotechnology

EC approves Aspaveli for C3G and primary IC-MPGN
16 January 2026
Chinese CDMO seeks to consolidate leadership in ADC space
16 January 2026
EC authorization for Waskyra for Wiskott-Aldrich syndrome
16 January 2026
Sun Pharma announces Unloxcyt US availability
16 January 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze